Macrophage Migration Inhibitory Factor (MIF) Tautomerase Inhibitors as Potential Novel Anti-Inflammatory Agents: Current Developments

被引:45
|
作者
Garai, Janos [2 ]
Lorand, Tamas [1 ]
机构
[1] Univ Pecs, Dept Biochem & Med Chem, Sch Med, H-7624 Pecs, Hungary
[2] Univ Pecs, Dept Pathophysiol & Gerontol, Sch Med, H-7624 Pecs, Hungary
关键词
MIF; anti inflammatory agent; inhibitor; curcuminoids; ISO-1; alpha; beta-unsaturated ketones; oxygen heterocycles; HYPOXIA-INDUCIBLE FACTOR; D-DOPACHROME TAUTOMERASE; P-BENZOQUINONE IMINE; MOLECULAR-DYNAMICS SIMULATIONS; ACTIVATED PROTEIN-KINASE; INDUCED BONE LOSS; NF-KAPPA-B; CRYSTAL-STRUCTURE; 4-OXALOCROTONATE TAUTOMERASE; PHENYLPYRUVATE TAUTOMERASE;
D O I
10.2174/092986709787581842
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Macrophage migration inhibitory factor (MIF), the pro-inflammatory cytokine, first described in 1966, plays an essential role in both, innate and adaptive immune response. It has been implicated in tumour growth and angiogenesis and it exerts an antagonistic action against glucocorticoid immunosuppressive effect. Its perplexing enzymatic tautomerase activity has attracted considerable interest in the last decade. It has been suggested, that a multitude of autoimmune/inflammatory/neoplastic disease states might benefit from therapeutic measures, targeting MIF. Hence, small molecule inhibitors of MIF are relentlessly sought as potential anti-inflammatory (antitumour) agents, while a true in vivo substrate for MIF still remains unidentified. One of the first studied MIF inhibitor group was the D-dopachrome family, and its carboxyderivatives have shown good inhibitory effect, as well as the fluorosubstituted phenylpyruvic acid class. The substance ISO-1 of isoxazoline skeleton was the first small molecular inhibitor of MIF, not related to its known substrates. N-acetyl-p-benzoquinone, an acetaminophen metabolite and its synthetic derivatives exerted submicromolar IC50 values. An acetylenic compound, the 2-oxo-4-phenyl-3-butynoate is a potent active-site-directed irreversible inhibitor of the phenyl pyruvate tautomerase activity of MIF. Some oxygen heterocycles, coumarines and chromenes, have also drawn attention as MIF inhibitors. The alpha,beta-unsaturated carbonyl compounds constitute a large novel class of MIF inhibitors. Several potent inhibitors were found among the cinnamic acid derivatives, the alpha,beta-unsaturated cyclic ketones, and the natural curcuminoids. Some other plant derived compounds were also studied. One of the latest developments in the field is the synthesis of AVP-13546, an exceptionally potent inhibitor. The structural pattern of MIF enzyme inhibitors exhibits wide variety; compounds having quite different molecular backbones belong to the MIF inhibitor family. In this paper, the separate classes of MIF inhibitors are discussed.
引用
收藏
页码:1091 / 1114
页数:24
相关论文
共 50 条
  • [21] Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
    Nishihira, Jun
    Mitsuyama, Keiichi
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (18) : 2104 - 2109
  • [22] Identification and Characterization of Novel Classes of Macrophage Migration Inhibitory Factor (MIF) Inhibitors with Distinct Mechanisms of Action
    Ouertatani-Sakouhi, Hajer
    El-Turk, Farah
    Fauvet, Bruno
    Cho, Min-Kyu
    Karpinar, Damla Pinar
    Le Roy, Didier
    Dewor, Manfred
    Roger, Thierry
    Bernhagen, Juergen
    Calandra, Thierry
    Zweckstetter, Markus
    Lashuel, Hilal A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (34) : 26581 - 26598
  • [23] Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities
    Valdez, Caroline Naomi
    Sanchez-Zuno, Gabriela Athziri
    Bucala, Richard
    Tran, Thuy T.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)
  • [24] Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link
    Conroy, H.
    Mawhinney, L.
    Donnelly, S. C.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (11) : 831 - 836
  • [25] Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity
    Al-Abed, Yousef
    Metz, Christine N.
    Cheng, Kai Fan
    Aljabari, Bayan
    VanPatten, Sonya
    Blau, Steven
    Lee, Hans
    Ochani, Mahendar
    Pavlov, Valentin A.
    Coleman, Thomas
    Meurice, Nathalie
    Tracey, Kevin J.
    Miller, Edmund J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (20) : 8224 - 8227
  • [26] Design, Synthesis, and Protein Crystallography of Biaryltriazoles as Potent Tautomerase Inhibitors of Macrophage Migration Inhibitory Factor
    Dziedzic, Pawel
    Cisneros, Jose A.
    Robertson, Michael J.
    Hare, Alissa A.
    Danford, Nadia E.
    Baxter, Richard H. G.
    Jorgensen, William L.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (08) : 2996 - 3003
  • [27] Identification of a novel enhancer in the first intron of Macrophage Migration Inhibitory Factor (MIF)
    Beaulieu, Elaine
    Ray, David W.
    McMaster, Andrew D.
    Tassabehji, May
    Donn, Rachelle
    INFLAMMATION RESEARCH, 2005, 54 : S155 - S155
  • [28] Aza-derivatives of resveratrol are potent inhibitors of macrophage migration inhibitory factor (MIF)
    Fujita, Yoshihiko
    Islam, Rafiqul Islam
    Kimura, Hideharu
    Matsumoto, Kazuko
    Furuta, Kazuyuki
    Nagai, Tomoyuki
    Kudo, Kanae
    Kaneda, Hiroyasu
    Tamura, Daisuke
    Sakai, Kazuko
    Aomatsu, Keiichi
    Arao, Tokuzo
    Okawara, Tadashi
    Nishio, Kazuto
    CANCER RESEARCH, 2011, 71
  • [29] Targeting macrophage migration inhibitory factor (MIF): a promising therapy for inflammatory ocular diseases
    Vazquez, Alicia
    Gonzalez, Marisol I.
    Reyes, Jose L.
    JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2023, 13 (01)
  • [30] The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model
    Kobold, Sebastian
    Merk, Melanie
    Hofer, Luisa
    Peters, Philip
    Bucala, Richard
    Endres, Stefan
    ONCOTARGET, 2014, 5 (01) : 103 - 107